Parkinson's disease management: Towards a new paradigm

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Guttman, Mark ^a   Suchowersky, Oksana ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; IMMUNOPHILIN; ISTRADEFYLLINE; LEVODOPA; NERVE GROWTH FACTOR; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN SURGERY; DRUG CHOICE; DRUG COST; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; HEALTH CARE POLICY; HOSPITAL COST; HUMAN; INTRANASAL DRUG ADMINISTRATION; LIVER TOXICITY; MEDICAL DECISION MAKING; MENTAL DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT INDICATION;

EID: 0032769411     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s031716710000010x     Document Type: Article

References (14)

1. Blanchet PJ. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Can J Neurol Sci 1999; (this issue).
2. Grimes DA, Lang AE. Treatment of early Parkinson's disease. Can J Neurol Sci 1999; (this issue).
3. Verhagen Metman VL, Del Dotto P, van der Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in PD. Neurology 1998; 50: 1323-1326.
4. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1998; 39: 29-36.
5. Rivest J, Barclay CL, Suchowersky O. COMT inhibitors in Parkinson's disease. Can J Neurol Sci 1999; (this issue).
6. Hobson DE, Pourcher E, Martin WRW. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci 1999; (this issue).
7. Honey C, Gross RE, Lozano AM. New developments in the surgery for Parkinson's disease. Can J Neurol Sci 1999; (this issue).
8. Greenmayre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist in rodent and primate models. Ann Neurol 1994; 35: 655-661.
9. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Nat Acad Sci 1997; 3: 421-428.
10. Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY. A double blind, placebo controlled study of intranasal apomorphine spray as rescue agent for off-states in Parkinson's disease. Mov Disord 1998; 13: 782-787.
11. Calabrese VP, Lloyd KA, Broncazio P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of Parkinsonism. Mov Disord 1998; 13: 768-774.
12. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380(6571): 252-255.
13. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507-513.
14. Guttman M for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-1065.